Patents Examined by Lorraine M. Spector
  • Patent number: 5399669
    Abstract: Recombinantly produced interleukin-2 exhibits human IL-2 activity, has a molecular weight of about 15,000 daltons, is activity stable at a pH of 2-9 and is resistant to elevated temperatures. The recombinant IL-2 has the principal biological activity of human IL-2, promotion of proliferation of cytotoxic T lymphocytes.
    Type: Grant
    Filed: July 26, 1993
    Date of Patent: March 21, 1995
    Assignees: Ajinomoto Co., Inc., Japanese Foundation For Cancer Research
    Inventors: Tadatsugu Taniguchi, Masami Muramatsu, Haruo Sugano, Hiroshi Matsui, Nobukazu Kashima, Junji Hamuro
  • Patent number: 5389529
    Abstract: Signal sequences based on LamB have been constructed. These signal sequences facilitate both the synthesis and secretion of neurotrophins in E. coli.
    Type: Grant
    Filed: November 21, 1991
    Date of Patent: February 14, 1995
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nikos Panayotatos, James P. Fandl
  • Patent number: 5374548
    Abstract: Novel fusions of a GPI signal domain and a polypeptide heterologous to the GPI signal domain donor polypeptide are provided for industrial use. Therapeutic administration of the GPI-linked product of the fusions enables the targeting of biological activity to cell membrane surfaces.
    Type: Grant
    Filed: February 12, 1993
    Date of Patent: December 20, 1994
    Assignee: Genentech, Inc.
    Inventor: Ingrid W. Caras
  • Patent number: 5371193
    Abstract: A novel mammalian cytokine, IL-11, and processes for producing it are disclosed. IL-11 may be used in pharmaceutical preparations for stimulating and/or enhancing cells involved in the immune response and cells involved in the proper functioning of the hematopoietic system.
    Type: Grant
    Filed: February 12, 1993
    Date of Patent: December 6, 1994
    Assignee: Genetics Institute, Inc. - Legal Affairs
    Inventors: Frances K. Bennett, Stephen R. Paul, Yu-Chung Yang
  • Patent number: 5367057
    Abstract: Isolated mammalian nucleic acid molecules encoding receptor protein tyrosine kinases expressed in primitive hematopoietic cells and not expressed in mature hematopoietic cells are provided. Also included are the receptors encoded by such nucleic acid molecules; the nucleic acid molecules encoding receptor protein tyrosine kinases having the sequences shown in FIG. 1 (murine flk-2), FIG. 2 (human flk-2) and FIG. 3 (murine flk-1); the receptor protein tyrosine kinases having the amino acid sequences shown in FIG. 1 (murine flk-2); FIG. 2 (human flk-2) and FIG. 3; ligands for the receptors; nucleic acid sequences that encode the ligands; and methods of stimulating the proliferation and/or differentiation of primitive mammalian hematopoietic stem cells comprising contacting the stem cells with a ligand that binds to a receptor protein tyrosine kinase expressed in primitive mammalian hematopoietic cells and not expressed in mature hematopoietic cells.
    Type: Grant
    Filed: April 30, 1993
    Date of Patent: November 22, 1994
    Assignee: The Trustees of Princeton University
    Inventor: Ihor R. Lemischka
  • Patent number: 5322936
    Abstract: Disclosed is recombinant penetrin polypeptide. Also disclosed is nucleic acid encoding penetrin, recombinant cells and plasmids encoding penetrin, antibodies directed against penetrin and various uses for penetrin and antibodies directed against penetrin.
    Type: Grant
    Filed: August 6, 1993
    Date of Patent: June 21, 1994
    Assignee: New England Medical Center Hospitals, Inc.
    Inventors: Miercio E. A. Pereira, Eduardo Ortega-Barria
  • Patent number: 5316922
    Abstract: This invention provides for improved means to produce binding specific proteins using concatamers of semi-randomly generated oligonucleotides inserted into genes encoding the external domains of bacterial outer membrane proteins. The genes are induced to express and the bacteria are then screened for the ability to bind to predetermined compositions. Those clones carrying the desired binding protein are isolated, cultured and the protein purified. Increased avidity of the binding specific proteins are achieved by reisolating the oligonucleotides which conferred binding affinity and mixing them with new semi-randomly generated oligonucleotides to generate a population enriched for oligonucleotides that had previously conferred to bacteria the desired binding affinity.
    Type: Grant
    Filed: April 15, 1992
    Date of Patent: May 31, 1994
    Assignee: The United States of America as represented by Department of Health and Human Services
    Inventors: Stanley Brown, Donald Court
  • Patent number: 5286483
    Abstract: The invention concerns antigens from the intraerythrocytic phase of Plasmodium falciparum, namely: a protein of 50 kDa with an isoelectric point of 5.5 and a protein of 65 kDa separated by electrophoresis in reducing conditions into two polypeptides of 47 and 18 kDa, both appearing in the serum of patients infected by Plasmodium falciparum or in the culture medium of this microorganism during its intraerythrocytic phase, as well as a protein of 126 kDa synthesized during the nuclear multiplication phase during schizogony and localized on the periphery of the schizonts at the parasitophore vacuole level, precursor of the 50 kDa and 65 kDa proteins. Application of these proteins in the preparation of vaccines against malaria, and monoclonal antibodies corresponding to the assay of the antibodies of an immunized subject and assay of the antigens according to the invention during an attack of malaria.
    Type: Grant
    Filed: February 26, 1991
    Date of Patent: February 15, 1994
    Inventors: Alain Vernes, Francois J. Dubrometz, Bernard Fortier, Patrick Deplace
  • Patent number: 5283354
    Abstract: Isolated mammalian nucleic acid molecules encoding receptor protein tyrosine kinases expressed in primitive hematopoietic cells and not expressed in mature hematopoietic cells are provided. Also included are the receptors encoded by such nucleic acid molecules; the nucleic acid molecules encoding receptor protein tyrosine kinases having the sequences shown in FIG. 1(flk-2) and FIG. 2 (flk-1); the receptor protein tyrosine kinases having the amino acid sequences shown in FIG. 1(flk-2) and FIG. 2 (flk-1); ligands for the receptors; nucleic acid sequences that encode the ligands; and methods of stimulating the proliferation of primitive mammalian hematopoietic stem cells comprising contacting the stem cells with a ligand that binds to a receptor protein tyrosine kinase expressed in primitive mammalian hematopoietic cells and not expressed in mature hematopoietic cells.
    Type: Grant
    Filed: September 17, 1992
    Date of Patent: February 1, 1994
    Assignee: The Trustees of Princeton University
    Inventor: Ihor R. Lemischka
  • Patent number: 5243041
    Abstract: A novel DNA sequence is disclosed which encodes a protein associated with many human cancers. This protein is designated as metallopanstimulin-1 (MPS-1) since (1) it is associated with metal ions, particularly zinc; (2) it has been detected in numerous different types of cells; (3) it is associated with rapid cell proliferation. The MPS-1 mRNA and its encoded protein are expressed in normal cells to a much lesser degree than in premalignant or malignant tumor cells, and they are present at very low levels in senescent cells compared to young healthy cells. The DNA sequence and the protein can be used in diagnostic methods such as detection of malignant cells associated with several types of tumors. Thus, this invention discloses a method for determining the presence of certain types of malignant conditions in patients. The MPS-1 cDNA sequence has been inserted into convenient vectors, and a culture of E.
    Type: Grant
    Filed: August 22, 1991
    Date of Patent: September 7, 1993
    Inventor: Jose A. Fernandez-Pol
  • Patent number: 5234822
    Abstract: Disclosed is recombinant penetrin polypeptide. Also disclosed is nucleic acid encoding penetrin, recombinant cells and plasmids encoding penetrin, antibodies directed against penetrin and various uses for penetrin and antibodies directed against penetrin.
    Type: Grant
    Filed: October 17, 1991
    Date of Patent: August 10, 1993
    Assignee: New England Medical Center Hospitals, Inc.
    Inventors: Miercio E. A. Pereira, Eduardo Ortega-Barria